Asenapine for Bipolar Depression

NCT ID: NCT01807741

Last Updated: 2017-07-24

Basic Information

• Recruitment Status: TERMINATED
• Clinical Phase: PHASE2
• Total Enrollment: 51 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2013-09-30
• Study Completion Date: 2017-07-31

Brief Summary

The purpose of this study is to compare asenapine with placebo in the treatment of depression associated with bipolar disorder, type I over eight weeks.

We hypothesize that patients will show significantly greater improvement with asenapine than placebo over eight weeks of treatment.

Detailed Description

86 patients with an episode of major depression associated with bipolar disorder, type I will be recruited by two sites for the study over fifteen months. Medication will be administered in a double-blind manner. Patients will receive asenapine (or placebo) beginning on day 0 at 5 mg bid. Dose may be increased to 10 mg bid and adjusted based on clinical response. Patients will be evaluated by a blinded (to treatment status) rater. Patients will be seen and ratings obtained at baseline (day 0) and on days 7, 14, 28, 42, and 56 (or termination from the study). Adverse events will be evaluated as well.

Conditions

Bipolar Depression

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: QUADRUPLE

Study Groups

Asenapine Group

Asenapine will be given beginning on day 0 at 5 mg bid. Dose will be increased to 10 mg bid if there is less than 50% decrease in MADRS score by week 2. Dose increases may be held if clinically indicated. Doses may be decreased at any time, if clinically indicated, by increments of 5 mg/day to a minimum of 5 mg qHS. Daily treatment with asenapine will be for 8 weeks.

Group Type: EXPERIMENTAL

Asenapine

Intervention Type: DRUG

Available in 5 and 10 mg.

Placebo Group

Sublingual tablets similar to the asenapine tablets.

Group Type: ACTIVE_COMPARATOR

Placebo

Intervention Type: DRUG

Interventions

Asenapine

Available in 5 and 10 mg.

Intervention Type: DRUG

Placebo

Intervention Type: DRUG

Other Intervention Names

Saphris; sugar pill

Eligibility Criteria

Inclusion Criteria

• Meet criteria for bipolar depression based on the MINI and confirmation of a previous manic or mixed episode
• 18-55 years of age
• Female patients must be using a medically accepted means of contraception (e.g. oral contraceptives, Depo-Provera, abstinence)
• Each patient must understand the nature of the study and must provide written informed consent
• Patients must have a diagnosis of bipolar disorder, type I and currently display an acute depressive episode as determined by M.I.N.I. (Sheehan et al, 1998)
• Patients must have a baseline (day 0) MADRS score ≥26
• Current episode of depression must have persisted for at least one month and no more than six months at study entry
• Subjects should be fluent in English

Exclusion Criteria

• Female patients who are either pregnant or lactating
• Clinically significant or unstable hepatic, renal, gastroenterologic, respiratory, cardiovascular, endocrinologic, immunologic, hematologic or other systemic medical conditions
• Any history of current or past diabetes that was treated with pharmacological intervention
• Neurological disorders including epilepsy, stroke, or severe head trauma
• Clinically significant laboratory abnormalities, on any of the following tests: CBC with differential, electrolytes, BUN, creatinine, hepatic transaminases, lipid profile, fasting glucose, urinalysis, thyroid indices and EKG
• Depression due to a general medical condition or substance-induced depression (DSM-IV)
• Mental retardation (IQ <70)
• Meeting criteria for a mixed episode, as defined by the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV)
• History of hypersensitivity to or intolerance of asenapine
• Prior history of asenapine non-response
• DSM-IV substance (except nicotine or caffeine) dependence within the past 3 months
• Judged clinically to be at suicidal risk (defined as having active suicidal ideation, intent or plan, or a serious suicide attempt within 30 days, or a baseline MADRS suicide score of >4)
• Participation in a clinical trial of another investigational drug within 1 month (30 days) prior to study entry
• Failure of the current depressive episode to respond to two or more pharmacological interventions
• Treatment with an injectable depot neuroleptic within less than one dosing interval between depot neuroleptic injections and day 0
• Schizophrenia or other psychotic disorders (including schizophreniform disorder, schizoaffective disorder, delusional disorder, brief psychotic disorder, shared psychotic disorder, psychotic disorder due to a general medical condition, substance-induced psychotic disorder, psychotic disorder not otherwise specified) as defined in the DSM-IV
• Major depressive disorder, dysthymic disorder, depressive disorder not otherwise specified

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 55 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

University of Louisville

OTHER

Sponsor Role: collaborator

Merck Sharp & Dohme LLC

INDUSTRY

Sponsor Role: collaborator

University of Cincinnati

OTHER

Sponsor Role: lead

Responsible Party

Caleb M. Adler

Professor

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Caleb M Adler, MD

Role: PRINCIPAL_INVESTIGATOR

University of Cincinnati

Locations

University of Cincinnati

Cincinnati, Ohio, United States

Countries

United States

Other Identifiers

2012-4181

Identifier Type: -

Identifier Source: org_study_id